• 同濟(jì)大學(xué)附屬東方醫(yī)院普外科（上海 200120）;

目的探討血清CA153、CA125和CA19-9檢測(cè)對(duì)乳腺癌早期診斷的價(jià)值。方法采用化學(xué)發(fā)光免疫法分別檢測(cè)乳腺癌、乳腺良性疾病患者及正常健康體檢者血清CA153、CA125和CA19-9的水平。結(jié)果乳腺癌患者血清的CA153、CA125和CA19-9的表達(dá)水平及表達(dá)陽(yáng)性率均明顯高于正常對(duì)照者和乳腺良性疾病患者(P lt;0.01)； 乳腺癌患者術(shù)后CA153、CA125及CA19-9表達(dá)水平較術(shù)前明顯下降(P lt;0.01)，與正常對(duì)照者比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P gt;0.05)。結(jié)論腫瘤標(biāo)志物CA153、CA125及CA19-9 對(duì)乳腺癌有一定的診斷價(jià)值，且可作為監(jiān)測(cè)乳腺癌病情進(jìn)展、評(píng)估治療療效及預(yù)后的指標(biāo)。

引用本文： 劉斌,孫國(guó)榮,王從俊,張輝,趙中辛. 血清CA153、CA125及CA19-9檢測(cè)對(duì)乳腺癌的診斷價(jià)值. 中國(guó)普外基礎(chǔ)與臨床雜志, 2011, 18(9): 991-992. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國(guó)普外基礎(chǔ)與臨床雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. 張喜慶, 王珠, 喬新民. 乳腺癌的現(xiàn)狀和遠(yuǎn)景 [J]. 中華外科雜志, 2002, 40(3): 161163.
2. Haglund C, Lundin J, Kuusela P, et al. CA242, a new tumour marker for pancreatic cancer: a comparison with CA199, CA50 and CEA [J]. Br J Cancer, 1994, 70(3): 487492.
3. Duffy MJ, Shering S, Sherry F, et al. CA153: a prognostic marker in breast cancer [J]. Int J Biol Markers, 2000, 15(4): 330333.
4. Jnicke F, Prechtl A, Thomssen C, et al; German N0 Study Group. Randomized adjuvant chemotherapy trial in highrisk, lymph nodenegative breast cancer patients identified by urokinasetype plasminogen activator and plasminogen activator inhibitor type 1 [J]. J Natl Cancer Inst, 2001, 93(12): 913920.
5. 李亞芬. 乳腺癌腫瘤標(biāo)志物的研究和臨床應(yīng)用進(jìn)展 [J]. 中國(guó)普外基礎(chǔ)與臨床雜志, 2002, 9(5): 298299.
6. Xu Y, Kimura N, Yoshida R, et al. Immunohistochemical study of Muc1, Muc2 and human gastric mucin in breast carcinoma: relationship with prognostic factors [J]. Oncol Rep, 2001, 8(5): 11771182.
7. Dupont WD, Parl FF, Hartmann WH, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia [J]. Cancer, 1993, 71(4): 12581265.
8. Ford HL, Kabingu EN, Bump EA, et al. Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIX1: A possible mechanism of breast carcinogenesis [J].Proc Natl Acad Sci U S A, 2004, 95(21): 1260812613.
9. Wang L, Shao ZM. Cyclin E expression and prognosis in breast cancer patients: a metaanalysis of published studies [J]. Cancer Invest, 2006, 24(6): 581587.
10. 劉揚(yáng)清, 鄭云會(huì). 血清CA153檢測(cè)對(duì)復(fù)發(fā)性乳腺癌的臨床價(jià)值 [J]. 中國(guó)腫瘤臨床與康復(fù), 2003, 10(6): 492494.
11. 徐鳳英, 田小平. CA125和SIL2R聯(lián)檢在診斷卵巢癌中應(yīng)用價(jià)值 [J]. 放射免疫學(xué)雜志, 2001, 14(5): 272273.
12. 苗曉, 周勤. 血清CA125在卵巢良惡性腫瘤診斷及監(jiān)控的臨床分析 [J]. 中外醫(yī)療, 2008, 27(31): 139140.
13. 楊鐘莉, 李輝, 張輝. 血清CA125、CEA、AFP聯(lián)檢對(duì)卵巢腫瘤的診斷價(jià)值 [J]. 山東醫(yī)藥, 2004, 44(27): 1314.
14. 陳光意, 蘇金明, 呂曉嫻. CEA、CA153及CA125對(duì)乳腺癌的診斷 [J]. 中國(guó)誤診學(xué)雜志, 2005, 5(5): 871872.
15. 陳建偉, 宋建國(guó). CA153, CEA及CA125聯(lián)合檢測(cè)對(duì)乳腺癌診斷的意義 [J]. 上海醫(yī)學(xué)檢驗(yàn)雜志, 2000, 15(4): 256.
16. 陳文思, 丁蓮, 王潭楓. 聯(lián)合檢測(cè)血清CA153、CA125、CA199對(duì)乳腺癌的臨床意義 [J]. 熱帶醫(yī)學(xué)雜志, 2007, 7(9): 879881.
17. Yang XR, Pfeiffer RM, GarciaClosas M, et al. Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a populationbased study [J]. Cancer Res, 2007, 6(21): 1060810617.
18. 段秋林, 李揚(yáng)威, 石峰, 等. 聯(lián)合檢測(cè)胃液中CEA、CA199、CA242在胃癌診斷中的應(yīng)用價(jià)值 [J]. 腫瘤防治研究, 2007, 34(8): 607609.
19. 張銘娜, 徐娟, 高燕, 等. 血清CA199在上皮性卵巢癌中的臨床意義 [J]. 天津醫(yī)藥, 2009, 37(3): 186188.
  1. 1. 張喜慶, 王珠, 喬新民. 乳腺癌的現(xiàn)狀和遠(yuǎn)景 [J]. 中華外科雜志, 2002, 40(3): 161163.
  2. 2. Haglund C, Lundin J, Kuusela P, et al. CA242, a new tumour marker for pancreatic cancer: a comparison with CA199, CA50 and CEA [J]. Br J Cancer, 1994, 70(3): 487492.
  3. 3. Duffy MJ, Shering S, Sherry F, et al. CA153: a prognostic marker in breast cancer [J]. Int J Biol Markers, 2000, 15(4): 330333.
  4. 4. Jnicke F, Prechtl A, Thomssen C, et al; German N0 Study Group. Randomized adjuvant chemotherapy trial in highrisk, lymph nodenegative breast cancer patients identified by urokinasetype plasminogen activator and plasminogen activator inhibitor type 1 [J]. J Natl Cancer Inst, 2001, 93(12): 913920.
  5. 5. 李亞芬. 乳腺癌腫瘤標(biāo)志物的研究和臨床應(yīng)用進(jìn)展 [J]. 中國(guó)普外基礎(chǔ)與臨床雜志, 2002, 9(5): 298299.
  6. 6. Xu Y, Kimura N, Yoshida R, et al. Immunohistochemical study of Muc1, Muc2 and human gastric mucin in breast carcinoma: relationship with prognostic factors [J]. Oncol Rep, 2001, 8(5): 11771182.
  7. 7. Dupont WD, Parl FF, Hartmann WH, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia [J]. Cancer, 1993, 71(4): 12581265.
  8. 8. Ford HL, Kabingu EN, Bump EA, et al. Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIX1: A possible mechanism of breast carcinogenesis [J].Proc Natl Acad Sci U S A, 2004, 95(21): 1260812613.
  9. 9. Wang L, Shao ZM. Cyclin E expression and prognosis in breast cancer patients: a metaanalysis of published studies [J]. Cancer Invest, 2006, 24(6): 581587.
  10. 10. 劉揚(yáng)清, 鄭云會(huì). 血清CA153檢測(cè)對(duì)復(fù)發(fā)性乳腺癌的臨床價(jià)值 [J]. 中國(guó)腫瘤臨床與康復(fù), 2003, 10(6): 492494.
  11. 11. 徐鳳英, 田小平. CA125和SIL2R聯(lián)檢在診斷卵巢癌中應(yīng)用價(jià)值 [J]. 放射免疫學(xué)雜志, 2001, 14(5): 272273.
  12. 12. 苗曉, 周勤. 血清CA125在卵巢良惡性腫瘤診斷及監(jiān)控的臨床分析 [J]. 中外醫(yī)療, 2008, 27(31): 139140.
  13. 13. 楊鐘莉, 李輝, 張輝. 血清CA125、CEA、AFP聯(lián)檢對(duì)卵巢腫瘤的診斷價(jià)值 [J]. 山東醫(yī)藥, 2004, 44(27): 1314.
  14. 14. 陳光意, 蘇金明, 呂曉嫻. CEA、CA153及CA125對(duì)乳腺癌的診斷 [J]. 中國(guó)誤診學(xué)雜志, 2005, 5(5): 871872.
  15. 15. 陳建偉, 宋建國(guó). CA153, CEA及CA125聯(lián)合檢測(cè)對(duì)乳腺癌診斷的意義 [J]. 上海醫(yī)學(xué)檢驗(yàn)雜志, 2000, 15(4): 256.
  16. 16. 陳文思, 丁蓮, 王潭楓. 聯(lián)合檢測(cè)血清CA153、CA125、CA199對(duì)乳腺癌的臨床意義 [J]. 熱帶醫(yī)學(xué)雜志, 2007, 7(9): 879881.
  17. 17. Yang XR, Pfeiffer RM, GarciaClosas M, et al. Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a populationbased study [J]. Cancer Res, 2007, 6(21): 1060810617.
  18. 18. 段秋林, 李揚(yáng)威, 石峰, 等. 聯(lián)合檢測(cè)胃液中CEA、CA199、CA242在胃癌診斷中的應(yīng)用價(jià)值 [J]. 腫瘤防治研究, 2007, 34(8): 607609.
  19. 19. 張銘娜, 徐娟, 高燕, 等. 血清CA199在上皮性卵巢癌中的臨床意義 [J]. 天津醫(yī)藥, 2009, 37(3): 186188.